Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study.

IF 0.9 4区 医学 Q4 UROLOGY & NEPHROLOGY
Matteo Massanova, Rebecca Vere, Sophie Robertson, Felice Crocetto, Biagio Barone, Lorenzo Dutto, Imran Ahmad, Mark Underwood, Jonathan Salmond, Amit Patel, Giuseppe Celentano, Jaimin R Bhatt
{"title":"Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study.","authors":"Matteo Massanova,&nbsp;Rebecca Vere,&nbsp;Sophie Robertson,&nbsp;Felice Crocetto,&nbsp;Biagio Barone,&nbsp;Lorenzo Dutto,&nbsp;Imran Ahmad,&nbsp;Mark Underwood,&nbsp;Jonathan Salmond,&nbsp;Amit Patel,&nbsp;Giuseppe Celentano,&nbsp;Jaimin R Bhatt","doi":"10.1097/CU9.0000000000000173","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To evaluate the predictive values of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2), prostate-specific antigen (PSA) level, PSA density (PSAD), digital rectal examination findings, and prostate volume, individually and in combination, for the detection of prostate cancer (PCa) in biopsy-naive patients.</p><p><strong>Methods: </strong>We retrospectively analyzed 630 patients who underwent transrectal systematic prostate biopsy following prostate multiparametric magnetic resonance imaging. A standard 12-core biopsy procedure was performed. Univariate and multivariate analyses were performed to determine the significant predictors of clinically significant cancer but not PCa.</p><p><strong>Results: </strong>The median age, PSA level, and PSAD were 70 years, 8.6 ng/mL, and 0.18 ng/mL/mL, respectively. A total of 374 (59.4%) of 630 patients were biopsy-positive for PCa, and 241 (64.4%) of 374 were diagnosed with clinically significant PCa (csPCa). The PI-RADS v2 score and PSAD were independent predictors of PCa and csPCa. The PI-RADS v2 score of 5 regardless of the PSAD value, or PI-RADS v2 score of 4 plus a PSAD of <0.3 ng/mL/mL, was associated with the highest csPCa detection rate (36.1%-82.1%). Instead, the PI-RADS v2 score of <3 and PSAD of <0.3 ng/mL/mL yielded the lowest risk of csPCa.</p><p><strong>Conclusion: </strong>The combination of the PI-RADS v2 score and PSAD could prove to be a helpful and reliable diagnostic tool before performing prostate biopsies. Patients with a PI-RADS v2 score of <3 and PSAD of <0.3 ng/mL/mL could potentially avoid a prostate biopsy.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"17 3","pages":"147-152"},"PeriodicalIF":0.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/e4/curr-urol-17-147.PMC10337816.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CU9.0000000000000173","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Background: To evaluate the predictive values of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2), prostate-specific antigen (PSA) level, PSA density (PSAD), digital rectal examination findings, and prostate volume, individually and in combination, for the detection of prostate cancer (PCa) in biopsy-naive patients.

Methods: We retrospectively analyzed 630 patients who underwent transrectal systematic prostate biopsy following prostate multiparametric magnetic resonance imaging. A standard 12-core biopsy procedure was performed. Univariate and multivariate analyses were performed to determine the significant predictors of clinically significant cancer but not PCa.

Results: The median age, PSA level, and PSAD were 70 years, 8.6 ng/mL, and 0.18 ng/mL/mL, respectively. A total of 374 (59.4%) of 630 patients were biopsy-positive for PCa, and 241 (64.4%) of 374 were diagnosed with clinically significant PCa (csPCa). The PI-RADS v2 score and PSAD were independent predictors of PCa and csPCa. The PI-RADS v2 score of 5 regardless of the PSAD value, or PI-RADS v2 score of 4 plus a PSAD of <0.3 ng/mL/mL, was associated with the highest csPCa detection rate (36.1%-82.1%). Instead, the PI-RADS v2 score of <3 and PSAD of <0.3 ng/mL/mL yielded the lowest risk of csPCa.

Conclusion: The combination of the PI-RADS v2 score and PSAD could prove to be a helpful and reliable diagnostic tool before performing prostate biopsies. Patients with a PI-RADS v2 score of <3 and PSAD of <0.3 ng/mL/mL could potentially avoid a prostate biopsy.

Abstract Image

Abstract Image

临床和前列腺多参数磁共振成像结果作为一般和临床显著前列腺癌风险的预测因素:一项回顾性单中心研究
背景:评估前列腺影像学报告和数据系统版本2 (PI-RADS v2)、前列腺特异性抗原(PSA)水平、PSA密度(PSAD)、直肠指检结果和前列腺体积(单独或联合)对活检患者前列腺癌(PCa)检测的预测价值。方法:我们回顾性分析630例经直肠系统前列腺活检后前列腺多参数磁共振成像的患者。进行标准的12芯活检。进行单因素和多因素分析以确定临床显著性癌症的重要预测因子,但不包括PCa。结果:中位年龄、PSA水平和PSAD分别为70岁、8.6 ng/mL和0.18 ng/mL。630例患者中有374例(59.4%)PCa活检阳性,374例患者中有241例(64.4%)诊断为临床显著性PCa (csPCa)。PI-RADS v2评分和PSAD是PCa和csPCa的独立预测因子。无论PSAD值如何,PI-RADS v2评分均为5分,或PI-RADS v2评分为4分+ PSAD。结论:PI-RADS v2评分与PSAD的结合可被证明是前列腺活检前有用且可靠的诊断工具。患者PI-RADS v2评分为
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Urology
Current Urology Medicine-Urology
CiteScore
2.30
自引率
0.00%
发文量
96
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信